Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Business Wire
Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior yearExpects fourth quarter and full year 2025 Recorlev® net revenue of $45 million and $139 million, respectivelyFull-year 2025 financial results and 2026 outlook planned for March 2, 2026 CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights."Our fourth quarter performance capped off a truly transformative 2025. Recorlev® delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year,” said John Shannon, Chief Executive Officer. “When combined with the stellar contributions of Gvoke® and Keveyis®, we expect total revenue of approximately $292 million, exceeding the high end of our full-year 2025 guidance.”Shannon contin
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]Yahoo! Finance
- Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 11/6/25 - Miss
XERS
Sec Filings
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- 1/8/26 - Form 8-K
- XERS's page on the SEC website